Business Standard

Sun Pharma rallies on FDA nod for cancer drug

USFDA have granted its subsidiary an approval for its ANDA for generic version of Doxil, Doxorubicin HCI liposome injection.

Related News

Sun Pharmaceutical Industries has rallied 4.4% to Rs 749 in morning trades after the company said US health regulators have approved a generic version of the drug Doxil.

“The U.S. Food and Drug Administration (USFDA) have granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCI liposome injection,” said in a statement.

It will be available in 20 milligram and 50 milligram vials, it added.

Doxorubicin HCI liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

The stock opened at Rs 735 and touched high of Rs 752 on the NSE. A combined around 960,000 shares have changed hands on the counter in early morning deals on both the exchanges.

 

Read more on:   
|
|

Read More

UCO Bank slips on declining net

Shares of UCO Bank has slumped after the bank posted a sharp drop in net profit for the third quarter ended December 31, 2012.

Quick Links

 

Market News

MF exposure to bank stocks surges in November

heir investments in banking stocks stood at Rs 70,575 crore as on November 30, 2014

Gold imports crawl in Dec

Only 15 tonne imported in the first half of the month due to adequate supply in the market, tepid demand

Markets end flat amid volatility; Fed stance, reforms cheer

The broader markets underperformed the benchmark indices- BSE Mid-Cap and Small-Cap indices fell over 1%

Oil surges from five-year low

West Texas Intermediate climbed 4.5 per cent in New York, the biggest gain since August 2012

Markets gain second day: Sensex adds 660 points in two days

Sensex up 1%, Nifty 0.8%; technology and metal lead

Back to Top